Scarica l'app Stockscreener
1.68
1.20%
0.02
Dopo l'orario di chiusura:
1.68
Okyo Pharma Limited Borsa (OKYO) Ultime notizie
OKYO SEC FilingsOKYO PHARMA LTD 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2026-03-31 02:21:38 - baoquankhu1.vn
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update - MarketBeat
How does OKYO Pharma Limited compare to its peersGlobal Markets & Accurate Buy Signal Notifications - baoquankhu1.vn
OKYO Earnings History & Surprises | EPS & Revenue Results | OKYO PHARMA LTD (NASDAQ:OKYO) - ChartMill
OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial - The Globe and Mail
OKYO Pharma director acquires additional shares on NASDAQ By Investing.com - Investing.com Australia
OKYO Pharma executive chairman linked entity acquires additional shares on NASDAQ - Investing.com
OKYO Pharma Announces Chairman and Founder Acquires Shares - The Manila Times
OKYO Pharma director acquires additional shares on NASDAQ - Investing.com UK
OKYO Pharma executive chairman increases stake with share purchase - Proactive Investors
OKYO Pharma (NASDAQ: OKYO) chair adds shares as NCP drug advances - Stock Titan
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3 - TipRanks
OKYO Pharma Announces Director Acquires Shares - The Manila Times
OKYO Pharma (NASDAQ: OKYO) director boosts stake with 5,000-share purchase - Stock Titan
OKYO Pharma director acquires 30,980 shares, increases total holding By Investing.com - in.investing.com
OKYO Pharma announces director stock purchase - proactiveinvestors.com
OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress - TipRanks
OKYO Pharma director acquires 30,980 shares, increases total holding - Investing.com
OKYO Pharma Limited Reports Share Acquisition by Chief Development Officer and Advances in Neuropathic Corneal Pain Therapy Development - Quiver Quantitative
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares - The Manila Times
OKYO Pharma (NASDAQ: OKYO) CDO buys 30,980 shares at $1.59 - Stock Titan
OKYO Pharma reports quality of life improvements in pain trial By Investing.com - Investing.com India
OKYO Pharma (OKYO) Chief Development Officer reports stock and option holdings - Stock Titan
OKYO Pharma (OKYO) director Cerrone reports 10.5M common-share stake on Form 3 - Stock Titan
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial - Proactive Investors
Urcosimod Phase 2 NCP data show QoL gains, OKYO Pharma (OKYO) plans Phase 2b/3 - Stock Titan
OKYO Pharma reports quality of life improvements in pain trial - Investing.com
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain - The Manila Times
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February - MarketBeat
OKYO Pharma (NASDAQ:OKYO) Stock Price Up 1.2%Time to Buy? - MarketBeat
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
OKYO Pharma prices public offering at $1.85/share to raise up to $20M - MSN
OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option - The Globe and Mail
OKYO Pharma (OKYO) lifts equity proceeds to $22M after option exercise - Stock Titan
Market Wrap: Is OKYO Pharma Limited a turnaround story2026 Momentum Check & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Geopolitics Watch: Will Coeptis Therapeutics Holdings Inc. Equity Warrant benefit from rate cutsQuarterly Portfolio Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Published on: 2026-03-07 08:54:47 - baoquankhu1.vn
Setup Watch: Can OKYO Pharma Limited maintain sales growthQuarterly Profit Review & Growth Focused Entry Point Reports - baoquankhu1.vn
Market Rankings: Is OKYO Pharma Limited stock trending bullishIndex Update & Capital Protection Trade Alerts - baoquankhu1.vn
OKYO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress - The Manila Times
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026 - Proactive Investors
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026 - TipRanks
OKYO Pharma's Urcosimod Selected for Presentation at ARVO 2026 Annual Meeting Following Positive Phase 2a Trial Results for Neuropathic Corneal Pain Treatment - Quiver Quantitative
OKYO (Nasdaq: OKYO) to present Fast Track NCP therapy data at ARVO 2026 - Stock Titan
Analysts Set OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Target Price at $6.00 - Defense World
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):